Choreo LLC Decreases Position in Zoetis Inc. $ZTS

Choreo LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 19.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,686 shares of the company’s stock after selling 5,293 shares during the period. Choreo LLC’s holdings in Zoetis were worth $3,173,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ZTS. Vanguard Group Inc. raised its stake in shares of Zoetis by 1.0% in the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after acquiring an additional 419,777 shares during the period. Geode Capital Management LLC boosted its stake in shares of Zoetis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after purchasing an additional 95,294 shares during the period. Norges Bank bought a new position in Zoetis during the 2nd quarter valued at about $809,491,000. Brown Advisory Inc. raised its position in Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after purchasing an additional 250,829 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Zoetis by 14.6% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after purchasing an additional 550,859 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS stock opened at $131.06 on Friday. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.00. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a fifty day simple moving average of $126.05 and a two-hundred day simple moving average of $134.05. The stock has a market capitalization of $55.32 billion, a price-to-earnings ratio of 21.77, a P/E/G ratio of 2.00 and a beta of 0.96.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter last year, the firm posted $1.40 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. BTIG Research reaffirmed a “buy” rating and set a $160.00 target price on shares of Zoetis in a research note on Thursday. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. KeyCorp assumed coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating for the company. Barclays started coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. Finally, Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.